Exploratory biomarker for target engagement
RARβ2 was not detected in WBCs isolated from plasma from placebo samples or the 1‐ and 12‐mg dosed MAD cohorts. In the MAD cohorts of 24, 75 and 100 mg dosing, RARβ2 expression upon ligand binding becomes upregulated and measurable (Figure Expression of retinoic acid receptor (RAR)β2 in white blood cells in multiple ascending dose cohorts. With increasing dose of KCL‐286 there is a corresponding increase of RARβ2, which is maintained at least until Day 14, final day of blood collection. Error bars denote standard deviation.